We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

62 hedge funds and large institutions have $1.18B invested in Kinnate Biopharma Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

13% more funds holding

Funds holding: 55 → 62 (+7)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

18% less capital invested

Capital invested by funds: $1.43B → $1.18B (-$251M)

Holders
62
Holders Change
+7
Holders Change %
+12.73%
% of All Funds
1.09%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.09%
New
25
Increased
13
Reduced
9
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$31.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$15.8M
3
LGM
Logos Global Management
California
+$12.7M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.29M
5
State Street
State Street
Massachusetts
+$6.39M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.1M
2
EAM
Eventide Asset Management
Massachusetts
-$6.96M
3
Invesco
Invesco
Georgia
-$6.66M
4
Millennium Management
Millennium Management
New York
-$3.57M
5
PHS
PFM Health Sciences
California
-$2.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
26
Franklin Resources
California
$5.45M – – –
American Century Companies
27
American Century Companies
Missouri
$5.41M +$5.8M +166,336 +2,331%
Northern Trust
28
Northern Trust
Illinois
$4.54M +$5.07M +145,608 New
AG
29
Artal Group
Luxembourg
$3.9M – – –
SCM
30
Soleus Capital Management
Connecticut
$3.4M +$3.8M +109,000 New
Victory Capital Management
31
Victory Capital Management
Texas
$3.19M -$151K -4,340 -4%
Charles Schwab
32
Charles Schwab
California
$2.76M +$3.09M +88,641 New
DCM
33
DAFNA Capital Management
California
$1.65M -$530K -15,206 -22%
N
34
Nuveen
North Carolina
$1.53M +$1.71M +49,186 New
TD Asset Management
35
TD Asset Management
Ontario, Canada
$1.39M +$224K +6,421 +17%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.11M +$1.25M +35,766 New
Bank of America
37
Bank of America
North Carolina
$847K +$947K +27,182 New
Deutsche Bank
38
Deutsche Bank
Germany
$845K +$945K +27,127 New
EC
39
EcoR1 Capital
California
$779K – – –
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$712K +$796K +22,845 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$635K +$710K +20,385 New
Goldman Sachs
42
Goldman Sachs
New York
$554K -$1.48M -42,512 -71%
Ensign Peak Advisors
43
Ensign Peak Advisors
Utah
$467K – – –
PL
44
Parkwood LLC
Ohio
$411K +$460K +13,198 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$364K +$408K +11,697 New
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$236K +$264K +7,566 New
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$227K +$254K +7,300 New
CPIG
48
Chicago Partners Investment Group
Illinois
$204K +$266K +7,620 New
MIM
49
MetLife Investment Management
New Jersey
$200K +$224K +6,421 New
JP Morgan Chase
50
JP Morgan Chase
New York
$158K +$177K +5,068 New
1
2
3 4

KNTE Hedge Fund Activity: Q1 2021 in Review

62 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2021, worth a combined $1.18B — down 18% from $1.43B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KNTE positions and 18 closed out — a net gain of 7 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $31.4M. The largest seller was Fidelity Investments, cutting an estimated $11.1M.

  • 62 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2021, up from 55 in Q4 2020.
  • Funds reported $1.18B of Kinnate Biopharma Inc. Common Stock stock for Q1 2021, down 18% quarter-over-quarter.
  • 25 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +7 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2021 was BlackRock, an estimated $31.4M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2021 was Fidelity Investments, an estimated $11.1M sold.

Based on aggregated 13F filings for Q1 2021.